Hyundai ADM Unveils a “New Paradigm in Cancer Treatment” – Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ — Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the “Biotech Showcase…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.